Posted in News
As noted in December 2019, a Tag for ATMP (advanced therapeutic medicinal products) has been created to enable Trusts to start to monitor their use of these products.
In January, Voretigene neparvovec (Luxturna) which is NICE approved (HST11) was added to dm+d and included in the Tag and in February 2020 tisagenlecleucel (Kymriah®) was also included in this Tag and the Cancer Drugs Fund Tag.
One common factor for each of these personalised treatments is that they are not ‘off the shelf’ pharmacy products. While the Tag will enable Trusts to track use through pharmacy, if these products are being sourced though other Departments within the Trust it will not be possible to map this use to dm+d from the current data sources.